Physician profile
Stacy K Lewis
NPI 1124021753
$57,065.98
in general payments reported to CMS, 2019-2025
8 companies · $19K in 2025
The $19K reported for 2025 was more than what 87% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.31 · 2023: $17K · 2024: $22K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $6,857 · Food and Beverage: $2,178 · Consulting Fee: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,190.00 |
| Travel and Lodging | $6,856.58 |
| Food and Beverage | $2,178.09 |
| Consulting Fee | $1,820.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $54,698.70 | 2023-2025 | Polivy, Columvi, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $1,951.25 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $144.72 | 2024 | Clonoseq |
| Gilead Sciences, INC. | $125.00 | 2023 | Trodelvy |
| Kite Pharma, INC. | $125.00 | 2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $21.31 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.